269 related articles for article (PubMed ID: 33247391)
21. Tolerance during 29 days of conventional dosing with cimetidine, nizatidine, famotidine or ranitidine.
Nwokolo CU; Smith JT; Gavey C; Sawyerr A; Pounder RE
Aliment Pharmacol Ther; 1990; 4 Suppl 1():29-45. PubMed ID: 1983345
[TBL] [Abstract][Full Text] [Related]
22. [Modern trends in the treatment of ulcer disease (clinical study of nizatidine "Galitidine")].
Dzambas D; Zivanović M; Majoros J; Petrović Z; Barjaktarović M; Hadnadev L; Tomić Z; Mrda Z; Damjanov D
Med Pregl; 1992; 45(9-10):353-8. PubMed ID: 1344473
[TBL] [Abstract][Full Text] [Related]
23. Effects of successive doses of nizatidine, cimetidine and ranitidine on serum gastrin level and gastric acid secretion.
Yamaji Y; Omata T; Abe T; Yoshida A; Ueki S; Aita H; Morita H; Chaki K; Segawa Y; Kurimoto T
Arzneimittelforschung; 1991 Sep; 41(9):954-7. PubMed ID: 1796924
[TBL] [Abstract][Full Text] [Related]
24. Effects of ranitidine and nizatidine on the risk of gastrointestinal cancer.
Kang H; Nam CM; Choi DW; Park S
Front Oncol; 2023; 13():1182174. PubMed ID: 37576886
[TBL] [Abstract][Full Text] [Related]
25. Simple and universal HPLC-UV method to determine cimetidine, ranitidine, famotidine and nizatidine in urine: application to the analysis of ranitidine and its metabolites in human volunteers.
Ashiru DA; Patel R; Basit AW
J Chromatogr B Analyt Technol Biomed Life Sci; 2007 Dec; 860(2):235-40. PubMed ID: 18006395
[TBL] [Abstract][Full Text] [Related]
26. Histamine-2 receptor antagonists do not alter serum ethanol levels in fed, nonalcoholic men.
Raufman JP; Notar-Francesco V; Raffaniello RD; Straus EW
Ann Intern Med; 1993 Apr; 118(7):488-94. PubMed ID: 8095127
[TBL] [Abstract][Full Text] [Related]
27. Pharmacokinetics of ranitidine and nizatidine in very elderly patients.
Sasaki M; Sudoh T; Fujimura A
Am J Ther; 2005; 12(3):223-5. PubMed ID: 15891265
[TBL] [Abstract][Full Text] [Related]
28. Changes in the effects of nizatidine and famotidine on cardiac performance after pretreatment with ranitidine.
Mescheder A; Ebert U; Halabi A; Kirch W
Eur J Clin Pharmacol; 1993; 45(2):151-6. PubMed ID: 8223837
[TBL] [Abstract][Full Text] [Related]
29. Comparison of 150 mg nizatidine BID or 300 mg at bedtime, and 150 mg ranitidine BID in the treatment of gastric ulcer--an 8-week randomized, double-blind multicentre study.
Di Mario F; Battaglia G; Naccarato R; D'Angelo A; Saggioro A; Da Broi GL; Vezzadini P; Bianchi Porro G
Hepatogastroenterology; 1990 Dec; 37 Suppl 2():62-5. PubMed ID: 1982108
[TBL] [Abstract][Full Text] [Related]
30. [Treatment of acute stomach ulcer with H2 receptor antagonists. A direct therapy comparison with 300 mg nizatidine nightly and 2 times 150 mg nizatidine with twice daily 150 mg ranitidine].
Arnold R; Beckenbach P; Bock H; Bormann R; Brunner G; Daake H; Dammann HG; Dietrich K; Fuerer M; Geiter B
Fortschr Med; 1989 Jun; 107(17):390-4. PubMed ID: 2568327
[TBL] [Abstract][Full Text] [Related]
31. Nizatidine versus ranitidine in the prevention of duodenal ulcer relapse. Six-month interim results of a European multicentre study.
Hentschel E; Schütze K; Reichel W; Kerstan E; Kratochvil P; Brandstätter G; Judmaier G; Keohane PP
Scand J Gastroenterol Suppl; 1987; 136():84-8. PubMed ID: 2892260
[TBL] [Abstract][Full Text] [Related]
32. Effects of histamine H(2)-receptor antagonists on human plasma levels of calcitonin gene-related peptide, substance P and vasoactive intestinal peptide.
Itoh H; Naito T; Takeyama M
J Pharm Pharmacol; 2002 Nov; 54(11):1559-63. PubMed ID: 12495560
[TBL] [Abstract][Full Text] [Related]
33. Therapeutic-interchange program for oral histamine H2-receptor antagonists.
Chase SL; Peterson AM; Wordell CJ
Am J Health Syst Pharm; 1998 Jul; 55(13):1382-6. PubMed ID: 9659966
[TBL] [Abstract][Full Text] [Related]
34. Nizatidine versus ranitidine in gastric ulcer disease. A European multicentre trial.
Naccaratto R; Cremer M; Dammann HG; Keohane PP; Mulder H; Sarles H; Simon B
Scand J Gastroenterol Suppl; 1987; 136():71-8. PubMed ID: 2892258
[TBL] [Abstract][Full Text] [Related]
35. Maintenance therapy of duodenal ulcer with H2-receptor antagonists--a meta-analysis.
Palmer RH; Frank WO; Karlstadt R
Aliment Pharmacol Ther; 1990 Jun; 4(3):283-94. PubMed ID: 1983324
[TBL] [Abstract][Full Text] [Related]
36. Nizatidine in the short-term treatment of duodenal ulcer--an Italian Multicenter Study.
Bovero E; Poletti M; Boero A; Mura BC; Camarri E; Corradini P; Corsini G; Federici G; Curzio M; Gianquinto G
Hepatogastroenterology; 1987 Dec; 34(6):269-71. PubMed ID: 2892768
[TBL] [Abstract][Full Text] [Related]
37. Role of H2-receptor antagonists in the treatment of duodenitis.
Laguzzi E; Blago MR; Girmania P; Sitar G
Tokai J Exp Clin Med; 1992 Jul; 17(2):63-6. PubMed ID: 1359681
[TBL] [Abstract][Full Text] [Related]
38. Comparative investigation of the influence of nizatidine, ranitidine, and cimetidine on the steady-state pharmacokinetics of theophylline in COPD patients.
Bachmann K; Sullivan TJ; Mauro LS; Martin M; Jauregui L; Levine L
J Clin Pharmacol; 1992 May; 32(5):476-82. PubMed ID: 1587967
[TBL] [Abstract][Full Text] [Related]
39. Rebound intragastric hyperacidity after abrupt withdrawal of histamine H2 receptor blockade.
Nwokolo CU; Smith JT; Sawyerr AM; Pounder RE
Gut; 1991 Dec; 32(12):1455-60. PubMed ID: 1685465
[TBL] [Abstract][Full Text] [Related]
40. Nizatidine and ranitidine in the short-term treatment of duodenal ulcer: a cooperative double-blind study of once-daily bedtime administration.
Pace F; Colombo E; Ferrara A; Prada A; Rocca F; Bianchi Porro G
Am J Gastroenterol; 1988 Jun; 83(6):643-5. PubMed ID: 2897784
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
